BRENZAVVY Drug Patent Profile

Which patents cover Brenzavvy, and when can generic versions of Brenzavvy launch?

Brenzavvy is a drug marketed by Theracosbio and is included in one NDA. There are seven patents protecting this drug.

The generic ingredient in BRENZAVVY is bexagliflozin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the bexagliflozin profile page.

DrugPatentWatch^® Generic Entry Outlook for Brenzavvy

Brenzavvy will be eligible for patent challenges on January 20, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 5, 2041. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BRENZAVVY

US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	37
Patent Applications:	217
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRENZAVVY
What excipients (inactive ingredients) are in BRENZAVVY?	BRENZAVVY excipients list
DailyMed Link:	BRENZAVVY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRENZAVVY

NDA:

214373

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BRENZAVVY

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

US Patents and Regulatory Information for BRENZAVVY

BRENZAVVY is protected by seven US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes			Y	Y
Theracosbio	BRENZAVVY	bexagliflozin	TABLET;ORAL	214373-001	Jan 20, 2023		RX	Yes	Yes			Y	Y

International Patents for BRENZAVVY

When does loss-of-exclusivity occur for BRENZAVVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

China

European Patent Office

Israel

Japan

Mexico

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BRENZAVVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	121997
Australia	2011264220
Brazil	112012031616

BRENZAVVY market dynamics and financial trajectory: sales uptake, pricing, payer access, exclusivity timeline, and competitive threats

Last updated: June 1, 2026

BRENZAVVY (notable-ingredient label name) is positioned for short-cycle growth driven by managed-care contracting and replacement of existing contraception and endometriosis-therapy options. Near-term revenue trajectory is constrained by (1) formulary access and prior-authorization patterns, (2) competitive alternatives with broader payer preferences, and (3) patent and exclusivity structure that affects timing of first generics or follow-on products.

H2: What market dynamics determine BRENZAVVY uptake and prescription growth?
Answer: Uptake is driven by payer coverage, net-price (rebates) vs. competitor benchmarks, and prescriber comfort tied to safety, dosing convenience, and clinical outcomes compared with existing hormonal and device-based options.

Key demand drivers

• Payer coverage and utilization management
  Coverage speed typically depends on whether BRENZAVVY is placed on preferred tiers without step therapy. Where plans require prior authorization or quantity limits, fill rates lag brand launch expectations.
• Net pricing vs. competitor “effective cost”
  Brand-to-brand competition in women’s health is often decided by net price after rebates. Plans anchor on lowest-cost preferred alternatives and may steer to those where rebates are sufficient to overcome formulary tiering.
• Clinical fit by patient segment
  Growth tends to concentrate where patient subgroups overlap the label’s highest-value outcomes and safety profile. Segment-specific prescribing raises persistence even when gross script counts look flat.
• Switching dynamics
  Contraception and related hormone markets show ramp-up from switches rather than only new starts. Where prescribers switch patients off older regimens, adoption can accelerate once early safety experience is established.

Supply and execution constraints

• Distribution readiness and pharmacy benefit manager (PBM) onboarding
  Script capture improves when BRENZAVVY is integrated quickly into PBM formularies and adjudication systems.
• Channel mix
  Retail pharmacy fills usually establish the headline script trend; specialty or mail-order mix matters for retention and contracting leverage.

H2: How much revenue can BRENZAVVY generate and what is the expected financial trajectory?
Answer: Financial trajectory is shaped by gross-to-net conversion, payer contracting cadence, and whether BRENZAVVY holds a preferred formulary position long enough to sustain repeat prescribing. Without a confirmed time-series of reported sales, only structural drivers can be mapped.

What moves the P&L

• Gross-to-net
  Rebate and discount levels influence the realized revenue per prescription. High rebate requirements to win access can cap net sales even when scripts grow.
• COGS and manufacturing scale
  Unit costs trend down with utilization. Early-stage ramp typically shows margin compression until volumes justify manufacturing throughput.
• Commercial spend Launch-period marketing and contracting costs can outpace revenue growth, pushing operating leverage out.

Scenario framework (what to watch in quarterly reporting)

• Script growth vs. persistence
  If prescriptions rise but discontinuations increase, revenue may plateau.
• Net price trend by payer channel Check whether ASP-like pricing is stable or pressured by tier changes.
• Trend in proportion of lives with preferred coverage Wide coverage without steep rebates supports healthier net revenue.

H2: When does BRENZAVVY lose exclusivity and how does that affect financial modeling?
Answer: Exclusivity loss timing determines when generic or follow-on competition can start. The financial model needs an exclusivity and patent-expiration schedule aligned to FDA application pathways.

Exclusivity and patent-driven competitive calendar (inputs needed for modeling)

• New chemical entity (NCE) exclusivity and/or other regulatory exclusivities
• Orange Book patent expiry
• Patent expiration and potential 180-day generic exclusivity triggers
• Patent litigation and settlements
• Pediatric exclusivity extensions (if any)
• Regulatory pathway dependencies
  • Paragraph IV for small-molecule generics
  • 505(b)(2) for reformulations or new indications
  • 505(j) vs. 505(b)(1) scenarios

H2: What Orange Book status applies to BRENZAVVY and which patents cover its use, formulation, and manufacturing?
Answer: Orange Book coverage determines whether generics face patent barriers and whether the first challenge can carve out carve-outs by claim.

Patent estate mapping needed for litigation risk

• Drug substance patents
• Drug product and formulation patents
• Method-of-use patents
• Manufacturing process patents
• Form factor-specific coverage
  • Tablets, injections, inserts, or other delivery systems
• Combination or regimen patents
  • If BRENZAVVY is part of a multi-agent regimen

How coverage drives generic timing

• Dominant barrier patents
  • If a formulation or method-of-use patent dominates, challenges may be delayed or limited.
• Multiple overlapping claims
  • Overlapping expiry dates can extend the “effective exclusivity” window even when one patent expires.

H2: Which companies are challenging BRENZAVVY with Paragraph IV filings or biosimilar-style equivalents?
Answer: Competitive filing pressure is typically reflected first in Paragraph IV notice filings and Orange Book “certifications.” The timing and number of challengers drive expected launch risk.

What to track

• Notice letter dates
• Certification type
  • ANDA with Paragraph IV vs. carve-out certifications
• Settlement terms
  • Launch-date triggers
  • “Design-around” agreements that limit IP entry
• Court schedules
  • Whether trials are set for patent-specific issues

H2: What patent litigation affects BRENZAVVY’s generic launch risk and valuation?
Answer: Litigation outcome is the key determinant of whether generic entry happens at first eligible date, later via settlement, or not at all.

Litigation signals that change market expectations

• Claim construction rulings
• Permanent injunction risk vs. damages-only outcomes
• Expedited trial schedules
• Settlement and consent judgment language
  • “30-month stay” effects for ANDA challengers
• Strength of asserted patents
  • Validity and enforceability history in similar families

H2: How does BRENZAVVY compare with competing contraception or hormonal therapies in pricing and formulary position?
Answer: Pricing power depends on whether BRENZAVVY is placed on preferred tiers, and whether net discounts remain competitive after rebates.

Competitor comparison dimensions

• Efficacy endpoints
  • If payer value assessments reward outcomes, formulary retention improves.
• Safety and tolerability
  • Lower discontinuation improves persistence and reduces “switch-back” costs.
• Dosing convenience
  • Less frequent dosing or fewer side effects supports higher continuation rates.
• Budget impact
  • PBMs and health plans weigh annual cost per member against alternatives.

H2: What financial impact do rebates, discounts, and payer negotiations have on BRENZAVVY net sales?
Answer: Net sales can diverge sharply from gross sales when PBM contracting requires high rebates to secure formulary placement.

Where rebate pressure typically appears

• During formulary committee annual cycles
• After competitor price moves
• When managed care broadens step therapy
• When payer switches preferred options based on budget impact

Metrics to watch

• Net-to-gross ratio trend
• Quarterly changes in trade promotions
• Retention of preferred formulary status across top PBMs
• Distribution of script volume across channels

H2: What generic entry risks exist for BRENZAVVY and what launch scenarios matter?
Answer: Generic entry risk depends on the overlap of expiry dates across the dominant Orange Book patents and whether challengers win early.

Launch scenarios used in valuation

• Early entry
  • Occurs if key patents are invalidated or not infringed and no effective settlement blocks.
• On-time entry
  • Happens at the first eligible launch date.
• Delayed entry due to settlements
  • Happens when a settlement pushes launch beyond patent expiry, often via delayed marketing agreements.
• Partial entry (carve-outs)
  • If method-of-use or formulation claims allow a narrow product launch, revenues may decline but not collapse.

H2: How do manufacturing/IP barriers and supply constraints affect BRENZAVVY revenue stability?
Answer: Revenue stability depends on whether supply meets demand without price concessions tied to shortages, and whether process patents complicate manufacturing replication.

Key barriers

• Process-specific patents
  • Can delay generic readiness by requiring non-infringing manufacturing design.
• Quality systems and comparability requirements
  • Batch-to-batch consistency drives time to commercial-ready supply.
• Regulatory inspection history
  • Affects time to launch for new entrants and can create temporary shortages.

H2: How does BRENZAVVY’s performance vary by geography and reimbursement environment?
Answer: U.S. reimbursement and formulary coverage dominate the financial picture for most brand models, while ex-U.S. expansion depends on local HTA and national formulary decisions.

Geographic considerations

• U.S.
  • PBM contracting, Medicare Part D preferred rules, and Medicaid rebate dynamics.
• EU and UK
  • HTA pricing thresholds and formularies influence uptake slower than in the U.S.
• Latin America and Asia
  • Tender systems and local approval timelines can delay scale but also create structured demand once listed.

H2: What commercial deal structure or licensing agreements could change BRENZAVVY’s financial trajectory?
Answer: Royalty rates, co-promotion economics, and milestone schedules determine whether net profitability scales with sales growth.

Deal levers

• Upfront and milestones
  • Can improve near-term cash flows even if net margin is modest initially.
• Tiered royalties
  • Raise returns when volume crosses thresholds and can incentivize aggressive payer contracting.
• Territory rights
  • If rights are split, revenue contribution depends on who owns contracting in each geography.

Key Takeaways

• BRENZAVVY’s revenue trajectory is primarily driven by formulary placement speed, net-price achieved through PBM contracting, and persistence driven by safety and dosing fit.
• Exclusivity and Orange Book patent structure set the generic entry calendar; litigation and settlements determine whether competition begins at earliest eligible dates or is pushed.
• Valuation and forecasting should track net-to-gross conversion, preferred formulary retention, script persistence, and Orange Book/Paragraph IV timelines to capture the inflection points that typically move market expectations.

FAQs

1. What Orange Book certifications for BRENZAVVY most directly predict an early generic launch?
2. How do settlement agreements for competing ANDAs typically shift BRENZAVVY forecasted revenue?
3. Which payer contracting patterns usually cause a brand like BRENZAVVY to see net price compression?
4. What metrics best indicate BRENZAVVY persistence versus simple new-start growth?
5. How should BRENZAVVY exclusivity and patent expiry be modeled for a partial (carve-out) generic entry scenario?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Approved Drug Products and Databases: Drug Trials Snapshots and related databases. U.S. Food and Drug Administration.
3. 21 U.S.C. § 355 (j) and related FDA ANDA regulatory framework for Paragraph IV certifications. U.S. Government Printing Office.